153 related articles for article (PubMed ID: 37855426)
1. Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testing.
Mavromati M; Saiji E; Demarchi MS; Lenoir V; Seipel A; Kuczma P; Jornayvaz FR; Becker M; Fernandez E; De Vito C; Triponez F; Leboulleux S
Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37855426
[TBL] [Abstract][Full Text] [Related]
2. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
[TBL] [Abstract][Full Text] [Related]
4. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
5. Ultrasonographic predictors of thyroid cancer in Bethesda III and IV thyroid nodules.
Alyusuf EY; Alhmayin L; Albasri E; Enani J; Altuwaijri H; Alsomali N; Arafah MA; Alyusuf Z; Jammah AA; Ekhzaimy AA; Alzahrani AS
Front Endocrinol (Lausanne); 2024; 15():1326134. PubMed ID: 38405143
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-guided fine needle aspiration cytology and ultrasound examination of thyroid nodules in the UAE: A comparison.
Al-Salam S; Sharma C; Abu Sa'a MT; Afandi B; Aldahmani KM; Al Dhaheri A; Yahya H; Al Naqbi D; Al Zuraiqi E; Mohamed BK; Almansoori SA; Al Zaabi M; Al Derei A; Al Shamsi A; Kaabi JA
PLoS One; 2021; 16(4):e0247807. PubMed ID: 33826647
[TBL] [Abstract][Full Text] [Related]
7. [On-site fine-needle aspiration cytology of thyroid nodules. Quality assurance of the Bethesda System for Reporting Thyroid Cytopathology (2008)].
Bak M; Péter I; Nyári T; Simon P; Újlaky M; Boér A; Kásler M
Orv Hetil; 2015 Oct; 156(41):1661-6. PubMed ID: 26551169
[TBL] [Abstract][Full Text] [Related]
8. Thyroid incidentalomas.
Jiskra J
Vnitr Lek; 2022; 68(7):465-474. PubMed ID: 36402574
[TBL] [Abstract][Full Text] [Related]
9. Rates of Malignancy in Cytology Indeterminate Thyroid Nodules: A Single Center Surgical Series.
Baraf L; Avidor Y; Bahat Dinur A; Yoel U; Samueli B; Joshua BZ; Fraenkel M
Isr Med Assoc J; 2023 Feb; 25(2):147-151. PubMed ID: 36841986
[TBL] [Abstract][Full Text] [Related]
10. Comparison of thyroid fine needle aspiration biopsy results before and after implementation of Bethesda classification.
Ozdemir D; Bestepe N; Faki S; Kilicarslan A; Parlak O; Ersoy R; Cakir B
Cytopathology; 2017 Oct; 28(5):400-406. PubMed ID: 28727204
[TBL] [Abstract][Full Text] [Related]
11. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
12. [Correlation between the Bethesda system for thyroid nodules and post-thyroidectomy histopathological diagnosis].
Kraus-Fischer G; Alvarado-Bachmann R; Rienzo-Madero B; Núñez-García E; Peña MV; Zerrweck-López C
Rev Med Inst Mex Seguro Soc; 2020 Apr; 58(2):114-121. PubMed ID: 34101555
[TBL] [Abstract][Full Text] [Related]
13. Malignancy outcomes and the impact of repeat fine needle aspiration of thyroid nodules with Bethesda category III cytology: A multicenter experience.
Köseoğlu D; Özdemir Başer Ö; Çetin Z
Diagn Cytopathol; 2021 Oct; 49(10):1110-1115. PubMed ID: 34196509
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification of the thyroid nodule with Bethesda indeterminate cytology, category III, IV, V on the one surgeon-performed US-guided fine-needle aspiration with 27-gauge needle, verified by histopathology of thyroidectomy: the additional value of one surgeon-performed elastography.
Sengul D; Sengul I; Van Slycke S
Acta Chir Belg; 2019 Feb; 119(1):38-46. PubMed ID: 30606092
[TBL] [Abstract][Full Text] [Related]
15. Malignancy Rates in Thyroid Nodules Classified as Bethesda III and IV; Correlating Fine Needle Aspiration Cytology with Histopathology.
Pereira C
Prague Med Rep; 2022; 123(4):243-249. PubMed ID: 36416462
[TBL] [Abstract][Full Text] [Related]
16. Correlation of TIRADS and Bethesda Scoring Systems with Final Histopathology of Thyroid Nodules - An Institutional Experience.
George NA; Suresh S; Jiji V; Renu S; Thomas S; Janardhan D; Jagathnath Krishna KM; Patil S; Samuel DM; George CK; Moideen SP
Indian J Otolaryngol Head Neck Surg; 2022 Dec; 74(Suppl 3):5753-5758. PubMed ID: 36742706
[TBL] [Abstract][Full Text] [Related]
17. The Value of Ultrasound-Guided Fine-Needle Aspiration Cytology Combined with Puncture Feeling in the Diagnosis of Thyroid Nodules.
Li L; Chen X; Li P; Liu Y; Ma X; Ye YQ
Acta Cytol; 2021; 65(5):368-376. PubMed ID: 34350849
[TBL] [Abstract][Full Text] [Related]
18. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
19. Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study.
Marina M; Zatelli MC; Goldoni M; Del Rio P; Corcione L; Martorana D; Percesepe A; Bonatti F; Mozzoni P; Crociara A; Ceresini G
J Endocrinol Invest; 2021 Dec; 44(12):2635-2643. PubMed ID: 33860907
[TBL] [Abstract][Full Text] [Related]
20. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
